Drug intelligence / Profile preview

Jaspisamide A

Development stage: Unknown
Modality: Small Molecules

Overview

Jaspisamide A is a marine macrolide toxin belonging to the trisoxazole family. It exhibits promising pharmacological properties due to its high-affinity and specific targeting of actin. Structurally, its trisoxazole ring interacts with actin subdomain 1, while its aliphatic side chain inserts into the hydrophobic cavity between actin subdomains 1 and 3. This binding site is analogous to that of the actin-capping domain of the gelsolin superfamily of proteins, suggesting that Jaspisamide A functions by severing and capping actin filaments, similar to gelsolin.

Targets

Actin filament proteins

Beyond the preview

Go deeper on Jaspisamide A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jaspisamide A.

Explore the full profile